Management of lower urinary tract symptoms in men with progressive neurological disease

Current Opinion in Urology

Volumn 16, Issue 1, 2006, Pages 30-36

  Woderich, René ^a   Fowler, Clare J ^a  

^a NATIONAL HOSPITAL FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

Author keywords

Benign prostatic hyperplasia; Bladder outlet obstruction; Detrusor overactivity; Incontinence; Lower urinary tract symptoms; Neurogenic bladder; Overactive bladder

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; BOTULINUM TOXIN A; CAPSAICIN; CHOLINERGIC RECEPTOR BLOCKING AGENT; DARIFENACIN; MUSCARINIC M3 RECEPTOR ANTAGONIST; MUSCARINIC RECEPTOR BLOCKING AGENT; OLVANIL; OXYBUTYNIN; RECEPTOR BLOCKING AGENT; RESINIFERATOXIN; SOLIFENACIN; TOLTERODINE; VANILLOID RECEPTOR 1;

BLADDER IRRIGATION; BLADDER NECK STENOSIS; CLINICAL TRIAL; CYSTOMETRY; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ELECTROMYOGRAPHY; HUMAN; MICTURITION; NEUROGENIC BLADDER; NEUROIMAGING; NEUROLOGIC DISEASE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERACTIVE BLADDER; PRIORITY JOURNAL; REVIEW; SPHINCTER; TREATMENT FAILURE; UNSPECIFIED SIDE EFFECT; URETHRA DISEASE; URINARY TRACT DISEASE; URODYNAMICS;

ADMINISTRATION, INTRAVESICAL; DIAGNOSTIC IMAGING; DISEASE PROGRESSION; ELECTROMYOGRAPHY; HUMANS; MALE; MUSCARINIC ANTAGONISTS; NERVOUS SYSTEM DISEASES; RANDOMIZED CONTROLLED TRIALS; URINARY BLADDER, NEUROGENIC; URODYNAMICS;

EID: 29944436171     PISSN: 09630643     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (76)

1. Gades NM, Jacobson DJ, Girman CJ, et al. Prevalence of conditions potentially associated with lower urinary tract symptoms in men. BJU Int 2005; 95:549-553.
2. Sakakibara R, Hamano S, Uchiyama T, et al. BPH patients have neurogenic detrusor dysfunction? A uro-neurological assessment. Urol Int 2005; 74:44-50. In this study, the authors show that neurological disease cannot be diagnosed or excluded on the basis of digital rectal examination and LUTS. UDS, neurological examination and MRI were required and therapeutic implications were significant.
3. Corcos J, Schick E. Textbook of the Neurogenic Bladder. London and New York: Martin Dunitz, Taylor & Francis Group plc; 2004.
4. Fowler CJ. Neurology of Bladder, Bowel, and Sexual Dysfunction. Boston: Butterworth-Heinemann; 1999.
5. Fowler CJ. Neurological disorders of micturition and their treatment. Brain 1999; 122:1213-1231.
6. Gomes CM, Arap S, Trigo-Rocha FE. Voiding dysfunction and urodynamic abnormalities in elderly patients. Rev Hosp Clin Fac Med Sao Paulo 2004; 59:206-215.
7. Stach-Lempinen B, Kirkinen P, Laippala P, et al. Do objective urodynamic or clinical findings determine impact of urinary incontinence or its treatment on quality of life? Urology 2004; 63:67-71 [discussion 71-2].
8. Khan MS, Chaliha C, Leskova L, Khullar V. The relationship between urinary symptom questionnaires and urodynamic diagnoses: an analysis of two methods of questionnaire administration. BJOG 2004; 111:468-474.
9. Defreitas GA, Lemack GE, Zimmern PE, et al. Distinguishing neurogenic from non-neurogenic detrusor overactivity: a urodynamic assessment of lower urinary tract symptoms in patients with and without Parkinson's disease. Urology 2003; 62:651-655.
10. Sakakibara R, Hattori T, Uchiyama T, Yamanishi T. Videourodynamic and sphincter motor unit potential analyses in Parkinson's disease and multiple system atrophy. J Neurol Neurosurg Psychiatry 2001; 71:600-606.
11. Chandiramani VA, Palace J, Fowler CJ. How to recognize patients with parkinsonism who should not have urological surgery. Br J Urol 1997; 80:100-104.
12. Thomas AW, Cannon A, Bartlett E, et al. The natural history of lower urinary tract dysfunction in men: the influence of detrusor underactivity on the outcome after transurethral resection of the prostate with a minimum 10-year urodynamic follow-up. BJU Int 2004; 93:745-750. This study has an impressive number of patients and 10 years minimum follow-up. It shows that symptoms and flowmetry are unreliable in detrusor underactivity, a condition in which TURP is unhelpful. The authors advocate routine preoperative urodynamic assessment for all men. Given the number of TURPs performed (e.g. 26 607 in England 2003-2004, Hospital Episode Statistics database), this would have enormous economic and workload implications.
13. McIntosh SL, Drinnan MJ, Griffiths CJ, et al. Noninvasive assessment of bladder contractility in men. J Urol 2004; 172:1394-1398. The cuff test is a simple, well tolerated, noninvasive study that estimates isovolumetric bladder pressure and produced encouraging first results. Could this be an alternative to invasive cystometry, helping to implement the proposals of [12••]?
14. Griffiths D. The New Urodynamics. In: International Continence Society 35th Annual Meeting; 2005; Montreal, Canada: International Continence Society; 2005.
15. Ockrim J, Laniado ME, Khoubehi B, et al. Variability of detrusor overactivity on repeated filling cystometry in men with urge symptoms: comparison with spinal cord injury patients. BJU Int 2005; 95:587-590. Men with idiopathic LUTS show two distinct responses to cystometry. One group adapted to repeated filling whereas symptoms persisted or increased in the other.
16. Wagg A, Bayliss M, Ingham NJ, et al. Urodynamic variables cannot be used to classify the severity of detrusor instability. Br J Urol 1998; 82:499-502.
17. Mirone V, Imbimbo C, Sessa G, et al. Correlation between detrusor collagen content and urinary symptoms in patients with prostatic obstruction. J Urol 2004; 172:1386-1389.
18. Horn T, Kortmann BB, Holm NR, et al. Routine bladder biopsies in men with bladder outlet obstruction? Urology 2004; 63:451-456.
19. Özkan B, Demirkesen O, Durak H, et al. Which factors predict upper urinary tract deterioration in overactive neurogenic bladder dysfunction? Urology 2005; 66:99-104. This small study suggests that severe to moderate perioperative detrusor fibrosis is a significant risk factor for upper tract deterioration following augmentation cystoplasty for NDO.
20. Palace J, Chandiramani VA, Fowler CJ. Value of sphincter electromyography in the diagnosis of multiple system atrophy. Muscle Nerve 1997; 20:1396-1403.
21. Paviour DC, Williams D, Fowler CJ, et al. Is sphincter electromyography a helpful investigation in the diagnosis of multiple system atrophy? A retrospective study with pathological diagnosis. Mov Disord 2005.
22. Wiseman OJ, Swinn MJ, Brady CM, Fowler CJ. Maximum urethral closure pressure and sphincter volume in women with urinary retention. J Urol 2002; 167:1348-1351 [discussion 1351-2].
23. Vodusek DB. Sphincter EMG and differential diagnosis of multiple system atrophy. Mov Disord 2001; 16:600-607.
24. Tison F, Arne P, Sourgen C, et al. The value of external anal sphincter electromyography for the diagnosis of multiple system atrophy. Mov Disord 2000; 15:1148-1157.
25. Lee EA, Kim BJ, Lee WY. Diagnosing multiple system atrophy with greater accuracy: combined analysis of the clonidine-growth hormone test and external anal sphincter electromyography. Mov Disord 2002; 17:1242-1247.
26. Kenton K, Fitzgerald MP, Brubaker L. Striated urethral sphincter activity does not alter urethral pressure during filling cystometry. Am J Obstet Gynecol 2005; 192:55-59.
27. Bartkowski DP, Doubrava RG. Ability of a normal dysfunctional voiding symptom score to predict uroflowmetry and external urinary sphincter electromyography patterns in children. J Urol 2004; 172:1980-1985 [discussion 1985].
28. Specht K, Minnerop M, Abele M, et al. In vivo voxel-based morphometry in multiple system atrophy of the cerebellar type. Arch Neurol 2003; 60:1431-1435.
29. Bosman T, Van Laere K, Santens P. Anatomically standardised 99mTc-ECD brain perfusion SPET allows accurate differentiation between healthy volunteers, multiple system atrophy and idiopathic Parkinson's disease. Eur J Nucl Med Mol Imaging 2003; 30:16-24.
30. Van Laere K, Santens P, Bosman T, et al. Statistical parametric mapping of 99mTc-ECD SPECT in idiopathic Parkinson's disease and multiple system atrophy with predominant parkinsonian features: correlation with clinical parameters. J Nucl Med 2004; 45:933-942.
31. Matsui H, Udaka F, Miyoshi T, et al. Brain perfusion differences between Parkinson's disease and multiple system atrophy with predominant parkinsonian features. Parkinsonism Relat Disord 2005; 11:227-232.
32. Lu CS, Weng YH, Chen MC, et al. 99mTc-TRODAT-1 imaging of multiple system atrophy. J Nucl Med 2004; 45:49-55.
33. Knudsen GM, Karlsborg M, Thomsen G, et al. Imaging of dopamine transporters and D2 receptors in patients with Parkinson's disease and multiple system atrophy. Eur J Nucl Med Mol Imaging 2004; 31:1631-1638.
34. Sakakibara R, Uchida Y, Uchiyama T, et al. Reduced cerebellar vermis activation during urinary storage and micturition in multiple system atrophy: 99mTc-labelled ECD SPECT study. Eur J Neurol 2004; 11:705-708. This SPECT study shows characteristic changes of brain activation (cerebellar vermis) during the voiding cycle. There are significant differences between MSA and normal controls.
35. Barkin J, Corcos J, Radomski S, et al. A randomized, double-blind, parallel-group comparison of controlled- and immediate-release oxybutynin chloride in urge urinary incontinence. Clin Ther 2004; 26:1026-1036.
36. Preik M, Albrecht D, O'Connell M, et al. Effect of controlled-release delivery on the pharmacokinetics of oxybutynin at different dosages: severity-dependent treatment of the overactive bladder. BJU Int 2004; 94:821-827.
37. Salvatore S, Khullar V, Cardozo L, et al. Long-term prospective randomized study comparing two different regimens of oxybutynin as a treatment for detrusor overactivity. Eur J Obstet Gynecol Reprod Biol 2005; 119:237-241.
38. Homma Y, Kawabe K. Health-related quality of life of Japanese patients with overactive bladder treated with extended-release tolterodine or immediate-release oxybutynin: a randomized, placebo-controlled trial. World J Urol 2004; 22:251-256.
39. Giannitsas K, Perimenis P, Athanasopoulos A, et al. Comparison of the efficacy of tolterodine and oxybutynin in different urodynamic severity grades of idiopathic detrusor overactivity. Eur Urol 2004; 46:776-782 [discussion 782-3].
40. Cardozo L, Lisec M, Millard R, et al. Randomized, double-blind placebo controlled trial of the once daily antimuscarinic agent solifenacin succinate in patients with overactive bladder. J Urol 2004; 172:1919-1924.
41. Haab F, Stewart L, Dwyer P. Darifenacin, an M3 selective receptor antagonist, is an effective and well-tolerated once-daily treatment for overactive bladder. Eur Urol 2004; 45:420-429 [discussion 429].
42. Foote J, Glavind K, Kralidis G, Wyndaele JJ. Treatment of overactive bladder in the older patient: pooled analysis of three phase III Studies of Darifenacin, an M3 selective Rreceptor antagonist. Eur Urol 2005; 48:471-477.
43. Abrams P, Swift S. Solifenacin is effective for the treatment of OAB dry Ppatients: a pooled analysis. Eur Urol 2005; 48:483-487.
44. Reynard JM. Does anticholinergic medication have a role for men with lower urinary tract symptoms/benign prostatic hyperplasia either alone or in combination with other agents? Curr Opin Urol 2004; 14:13-16.
45. Athanasopoulos A, Gyftopoulos K, Giannitsas K, et al. Combination treatment with an alpha-blocker plus an anticholinergic for bladder outlet obstruction: a prospective, randomized, controlled study. J Urol 2003; 169:2253-2256.
46. DuBeau CE, Khullar V, Versi E. 'Unblinding' in randomized controlled drug trials for urinary incontinence: Implications for assessing outcomes when adverse effects are evident. Neurourol Urodyn 2005; 24:13-20.
47. Lazzeri M, Spinelli M, Zanollo A, Turini D. Intravesical vanilloids and neurogenic incontinence: ten years experience. Urol Int 2004; 72:145-149.
48. Watanabe T, Yokoyama T, Sasaki K, et al. Intravesical resiniferatoxin for patients with neurogenic detrusor overactivity. Int J Urol 2004; 11:200-205.
49. Silva C, Silva J, Ribeiro MJ, et al. Urodynamic effect of intravesical resiniferatoxin in patients with neurogenic detrusor overactivity of spinal origin: results of a double-blind randomized placebo-controlled trial. Eur Urol 2005. This is the first placebo-controlled trial to prove the clinical efficacy of intravesical resiniferatoxin in human spinal NDO.
50. Dinis P, Silva J, Ribeiro MJ, et al. Bladder C-fiber desensitization induces a long-lasting improvement of BPH-associated storage LUTS: a pilot study. Eur Urol 2004; 46:88-93 [discussion 93-4].
51. Kuo HC. Multiple intravesical instillation of low-dose resiniferatoxin is effective in the treatment of detrusor overactivity refractory to anticholinergics. BJU Int 2005; 95:1023-1027.
52. Brady CM, Apostolidis AN, Harper M, et al. Parallel changes in bladder suburothelial vanilloid receptor TRPV1 and pan-neuronal marker PGP9.5 immunoreactivity in patients with neurogenic detrusor overactivity after intravesical resiniferatoxin treatment. BJU Int 2004; 93:770-776. Insight into the mechanism of action of intravesical vanilloids in human spinal NDO. Provides significant evidence for the role of increased suburothelial afferent innervation in the pathophysiology of the condition in humans. Increased sensory receptor TRPV1 levels were identified in the suburothelium of patients with spinal NDO, which were dramatically decreased only in clinical responders to the treatment.
53. Apostolidis A, Brady CM, Yiangou Y, et al. Capsaicin receptor TRPV1 in urothelium of neurogenic human bladders and effect of intravesical resiniferatoxin. Urology 2005; 65:400-405. For the first time, the authors of [52•] demonstrate increased afferent innervation and receptor TRPV levels in the urothelium of human spinal NDO and analyse their pathopysiology and response to vanilloid instillation.
54. Brady CM, Apostolidis A, Yiangou Y, et al. P2X3-immunoreactive nerve fibres in neurogenic detrusor overactivity and the effect of intravesical resiniferatoxin. Eur Urol 2004; 46:247-253.
55. Appendino G, De Petrocellis L, Trevisani M, et al. Development of the first ultra-potent 'capsaicinoid' agonist at transient receptor potential vanilloid type 1 TRPV1 channels and its therapeutic potential. J Pharmacol Exp Ther 2005; 312:561-570.
56. Cruz F, Silva C. Botulinum toxin in the management of lower urinary tract dysfunction: contemporary update. Curr Opin Urol 2004; 14:329-334.
57. Sahai A, Khan M, Fowler CJ, Dasgupta P. Botulinum toxin for the treatment of lower urinary tract symptoms: a review. Neurourol Urodyn 2005; 24:2-12.
58. Jost WH, Naumann M. Botulinum toxin in neuro-urological disorders. Mov Disord 2004; 19(Suppl 8):S142-S145.
59. Popat R, Apostolidis A, Kalsi V, et al. A comparison between the response of patients with idiopathic detrusor overactivity and neurogenic detrusor overactivity to the first intradetrusor injection of botulinum-A toxin. J Urol 2005; 174:984-988.
60. Werner M, Schmid DM, Schussler B. Efficacy of botulinum-A toxin in the treatment of detrusor overactivity incontinence: a prospective nonrandomized study. Am J Obstet Gynecol 2005; 192:1735-1740.
61. Kessler TM, Danuser H, Schumacher M, et al. Botulinum A toxin injections into the detrusor: an effective treatment in idiopathic and neurogenic detrusor overactivity? Neurourol Urodyn 2005; 24:231-236.
62. Schulte-Baukloh H, Weiss C, Stolze T, et al. Botulinum-A toxin for treatment of overactive bladder without detrusor overactivity: urodynamic outcome and patient satisfaction. Urology 2005; 66:82-87.
63. Reitz A, Stohrer M, Kramer G, et al. European experience of 200 cases treated with botulinum-A toxin injections into the detrusor muscle for urinary incontinence due to neurogenic detrusor overactivity. Eur Urol 2004; 45:510-515. This multicentre European study remains to date the largest series to report the results of the use of BTX injections in the bladder of patients with NDO.
64. Grosse J, Kramer G, Stohrer M. Success of repeat detrusor injections of botulinum a toxin in patients with severe neurogenic detrusor overactivity and incontinence. Eur Urol 2005; 47:653-659. In antimuscarinic-resistant NDO, repeat injections with BTX are as effective and safe as the first. Long-term conservative management of this challenging problem now seems possible.
65. Schurch B, de Seze M, Denys P, et al. Botulinum toxin type a is a safe and effective treatment for neurogenic urinary incontinence: results of a single treatment, randomized, placebo controlled 6-month study. J Urol 2005; 174:196-200. This is the first placebo-controlled trial to prove the clinical efficacy of intra-detrusor BTX-A in human spinal NDO.
66. Hajebrahimi S, Altaweel W, Cadoret J, et al. Efficacy of botulinum-A toxin in adults with neurogenic overactive bladder: initial results. Can J Urol 2005; 12:2543-2546.
67. Maria G, Brisinda G, Civello IM, et al. Relief by botulinum toxin of voiding dysfunction due to benign prostatic hyperplasia: results of a randomized, placebo-controlled study. Urology 2003; 62:259-264 [discussion 264-5].
68. Kuo HC. Prostate botulinum A toxin injection - an alternative treatment for benign prostatic obstruction in poor surgical candidates. Urology 2005; 65:670-674.
69. Haferkamp A, Schurch B, Reitz A, et al. Lack of ultrastructural detrusor changes following endoscopic injection of botulinum toxin type a in overactive neurogenic bladder. Eur Urol 2004; 46:784-791.
70. Apostolidis A, Popat R, Yiangou Y, et al. Decreased sensory receptors P2x3 and TRPV1 in suburothelial nerve fibers following intradetrusor injections of botulinum toxin for human detrusor overactivity. J Urol 2005; 174:977-983. This immunohistochemical study is the first to demonstrate a possible mechanism of action of BTX A in the overactive human bladder. BTX A was found to decrease sensory receptor levels in intact suburothelial afferent fibres, providing evidence for pharmacological afferent neuromodulation of abnormal bladder pathways.
71. Khera M, Somogyi GT, Salas NA, et al. In vivo effects of botulinum toxin A on visceral sensory function in chronic spinal cord-injured rats. Urology 2005; 66:208-212.
72. Smith CP, Vemulakonda VM, Kiss S, et al. Enhanced ATP release from rat bladder urothelium during chronic bladder inflammation: effect of botulinum toxin A. Neurochem Int 2005; 47:291-297.
73. Atiemo H, Wynes J, Chuo J, et al. Effect of botulinum toxin on detrusor overactivity induced by intravesical adenosine triphosphate and capsaicin in a rat model. Urology 2005; 65:622-626.
74. Chuang YC, Yoshimura N, Huang CC, et al. Intravesical botulinum toxin a administration produces analgesia against acetic acid induced bladder pain responses in rats. J Urol 2004; 172:1529-1532.
75. El-Hakim A. Chronic prostatitis/chronic pelvic pain syndrome: is there a role for local drug infiltration therapy? J Endourol 2004; 18:227-231.
76. Smith CP, Nishiguchi J, O'Leary M, et al. Single-institution experience in 110 patients with botulinum toxin A injection into bladder or urethra. Urology 2005; 65:37-41.